Ndlovu Care Center | Research and Lab

Location: SOUTH AFRICA

About the Facility:

Completed in Fall 2017, this lab facility serves over 7,600 HIV+ individuals in need of antiretroviral treatment and provides the Ndlovu Care Group with an HIV/AIDS vaccine and tuberculosis vaccine research facility.

This project is the second phase of the existing Ndlovu Care Group facility. The first phase provided the community with a 12-hour clinic and a 24-hour maternity ward. The first phase of the clinic treats 11,000 patients, 7,600 of whom are currently seeking treatment for HIV. The Ndlovu Research Center phase two is a two-story solar-powered facility, which features a patient waiting area and care clinic with a one floor research facility and laboratory.

Why …?

The areas served by this facility are considered “Presidential Poverty Nodes of Rural South Africa”. They see high unemployment rates, low education rates and prenatal HIV rates between 19 and 27 percent.

Project Partners:

Ndlovu Care Group (Fred Hutchinson Cancer Research Center, Infectious Disease Research Institute)

The Ndlovu Health Care Group has made tremendous steps to help combat and treat HIV/AIDS in communities in South Africa. They have tested thousands of people within the surrounding communities for HIV/AIDS and provided them with the necessary care and medication. For the past 23 years, Ndlovu has emphasized compassion and proper care for their patients, thus restoring the hope and well being of many through free and adequate health care.